These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

722 related items for PubMed ID: 29710216

  • 1. Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib.
    Schuetze SM, Bolejack V, Thomas DG, von Mehren M, Patel S, Samuels B, Choy E, D'Amato G, Staddon AP, Ganjoo KN, Chow WA, Rushing DA, Forscher CA, Priebat DA, Loeb DM, Chugh R, Okuno S, Reinke DK, Baker LH.
    JAMA Oncol; 2018 Jun 01; 4(6):814-820. PubMed ID: 29710216
    [Abstract] [Full Text] [Related]

  • 2. Survival of advanced/recurrent gastrointestinal stromal tumors treated with tyrosine kinase inhibitors in Taiwan: a nationwide registry study.
    Tsai HJ, Shan YS, Yang CY, Hsiao CF, Tsai CH, Wang CC, Lin MT, Ting CF, Chan DC, Chen TH, Yen CC, Chen YY, Lin HY, Yeh TS, Ho CL, Shieh TY, Bai LY, Hsu JT, Chen IS, Chen LT, Yeh CN, Taiwan Cooperative Oncology Group (TCOG) GIST Study Group.
    BMC Cancer; 2024 Jul 11; 24(1):828. PubMed ID: 38992597
    [Abstract] [Full Text] [Related]

  • 3. Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.
    Heinrich MC, Rankin C, Blanke CD, Demetri GD, Borden EC, Ryan CW, von Mehren M, Blackstein ME, Priebat DA, Tap WD, Maki RG, Corless CL, Fletcher JA, Owzar K, Crowley JJ, Benjamin RS, Baker LH.
    JAMA Oncol; 2017 Jul 01; 3(7):944-952. PubMed ID: 28196207
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Identifying Secondary Mutations in Chinese Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) by Next Generation Sequencing (NGS).
    Du J, Wang S, Wang R, Wang SY, Han Q, Xu HT, Yang P, Liu Y.
    Pathol Oncol Res; 2020 Jan 01; 26(1):91-100. PubMed ID: 31758409
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Clinical outcomes of imatinib dose escalation versus sunitinib in first-line imatinib-failure gastrointestinal stromal tumour.
    Yang W, Li K, Yu J, Shou C, Zhang Q, Hong Y, Sun J, Yu H, Gao Y, Shen Q, Zhao Z, Zheng S.
    Scand J Gastroenterol; 2018 Jan 01; 53(10-11):1328-1334. PubMed ID: 30346846
    [Abstract] [Full Text] [Related]

  • 9. Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib.
    Serrano C, García-Del-Muro X, Valverde C, Sebio A, Durán J, Manzano A, Pajares I, Hindi N, Landolfi S, Jiménez L, Rubió-Casadevall J, Estival A, Lavernia J, Safont MJ, Pericay C, Díaz-Beveridge R, Martínez-Marín V, Vicente-Baz D, Vivancos A, Hernández-Losa J, Arribas J, Carles J.
    Oncologist; 2019 May 01; 24(5):680-687. PubMed ID: 30126859
    [Abstract] [Full Text] [Related]

  • 10. [Clinicopathological features and prognosis of gastrointestinal stromal tumors with KIT/PDGFRA gene "homozygous mutation": a multicenter retrospective cohort study].
    Shen YY, Li XQ, Yang LX, Fang Y, Nie MM, He ZR, Hou YY, Cao H, Wang M, Shen KT.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep 25; 24(9):804-813. PubMed ID: 34530562
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib.
    Verboom MC, Kloth JSL, Swen JJ, van der Straaten T, Bovée JVMG, Sleijfer S, Reyners AKL, Mathijssen RHJ, Guchelaar HJ, Steeghs N, Gelderblom H.
    Eur J Cancer; 2017 Nov 25; 86():226-232. PubMed ID: 29054076
    [Abstract] [Full Text] [Related]

  • 13. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
    Nishida T, Doi T, Naito Y.
    Expert Opin Pharmacother; 2014 Oct 25; 15(14):1979-89. PubMed ID: 24990162
    [Abstract] [Full Text] [Related]

  • 14. Current research and treatment for gastrointestinal stromal tumors.
    Lim KT, Tan KY.
    World J Gastroenterol; 2017 Jul 21; 23(27):4856-4866. PubMed ID: 28785140
    [Abstract] [Full Text] [Related]

  • 15. Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study.
    Kang YK, George S, Jones RL, Rutkowski P, Shen L, Mir O, Patel S, Zhou Y, von Mehren M, Hohenberger P, Villalobos V, Brahmi M, Tap WD, Trent J, Pantaleo MA, Schöffski P, He K, Hew P, Newberry K, Roche M, Heinrich MC, Bauer S.
    J Clin Oncol; 2021 Oct 01; 39(28):3128-3139. PubMed ID: 34343033
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.
    Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA.
    J Clin Oncol; 2003 Dec 01; 21(23):4342-9. PubMed ID: 14645423
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors.
    Lim KH, Huang MJ, Chen LT, Wang TE, Liu CL, Chang CS, Liu MC, Hsieh RK, Tzen CY.
    Med Oncol; 2008 Dec 01; 25(2):207-13. PubMed ID: 18488160
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.